

AMENDMENTS TO THE CLAIMS

Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

1. (Previously presented) A pharmaceutical composition comprising Annexin V protein or an N-terminal fragment of Annexin V, or a corresponding salt thereof.
2. (Canceled)
3. (Previously presented) The method of claim 4, wherein the effective amount of the Annexin V in the pharmaceutical composition is determined from a diagnostic status analysis of Annexin V-endothelium binding in said subject.
4. (Currently amended) A method of ~~treating a subject at risk of atherothrombosis and/or preventing plaque rupture in a subject~~ comprising administering to said subject a pharmaceutical composition comprising an effective amount of Annexin V ~~or N-terminal fragment of Annexin V or a corresponding salt thereof~~.
5. (Previously presented) The method according to claim 4, wherein the subject at risk is a systemic lupus erythematosus (SLE) patient.
6. (Previously presented) A pharmaceutical composition comprising a purified subfraction of pooled immunoglobulins with the capacity to inhibit antibodies binding to Annexin V, or a purified subfraction of pooled immunoglobulins with the capacity to promote binding of Annexin V to endothelium.
7. (Canceled)
8. (Previously presented) A method of treating a subject at risk of atherothrombosis and/or plaque rupture comprising administering to said subject a pharmaceutical composition comprising an effective amount of pooled immunoglobulins with the capacity to inhibit antibodies binding to Annexin V or a purified subfraction of pooled immunoglobulins with the capacity to promote binding of Annexin V to endothelium.

9. (Previously presented) The method according to claim 8, wherein the subject at risk is a systemic lupus erythematosus (SLE) patient.
10. (Previously presented) The method according to claim 4, wherein said subject exhibits vulnerable plaques.
11. (Previously presented) The method according to claim 8, wherein said subject exhibits vulnerable plaques.
12. (Previously presented) The pharmaceutical composition of claim 6, wherein the immunoglobulins with the capacity to promote binding of Annexin V to endothelium are antibodies that can decrease the inhibitory effect of serum with a high antiphospholipid antibody titre on the binding of Annexin V to endothelial cells, anti-aPAF antibodies, anti-IgG antibodies and/or an intravenous immunoglobulin preparation from pooled plasma.
13. (Previously presented) The method of claim 8, wherein the immunoglobulins with the capacity to promote binding of Annexin V to endothelium are antibodies that can decrease the inhibitory effect of serum with a high antiphospholipid antibody titre on the binding of Annexin V to endothelial cells, anti-aPAF antibodies, anti-IgG antibodies and/or an intravenous immunoglobulin preparation from pooled plasma.